GlassScriptPhysician profile
Martin D Fleming
NPI 1578673836
$703.89
in general payments reported to CMS, 2019-2025
12 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.73 · 2022: $305 · 2023: $117 · 2024: $125 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $159.95 | 2022-2024 | Restrata Wound Matrix |
| Tempus Ai, INC | $134.01 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $116.70 | 2022-2025 | Keytruda |
| Integra Lifesciences Corporation | $75.03 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Ethicon US, LLC | $57.65 | 2021-2022 | |
| Lilly USA, LLC | $45.96 | 2022 | |
| Gilead Sciences, INC. | $23.03 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.68 | 2024 | Exparel |
| E.R. Squibb & Sons, L.L.C. | $21.02 | 2025 | Opdualag |
| Reprise Biomedical, INC. | $18.64 | 2025 | Miro 3d |
| Amgen INC. | $15.17 | 2022 | |
| Myriad Genetic Laboratories, INC. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.